NImmune Biopharma to Present Omilancor Progress at UBS Symposium
Key Insights
NImmune Biopharma (search) will participate in the UBS Virtual Biotechnology Private Company Symposium on September 18-19, 2024.
CEO Josep Bassaganya-Riera will present updates on NImmune's immunoregulatory therapeutics pipeline.
Omilancor, a Phase 3 therapeutic targeting LANCL2 (search) for ulcerative colitis (search) and Crohn’s disease (search), will be a key focus.
NImmune Biopharma (search), a company focused on precision inflammation & immunology (I&I) therapeutics, announced that its Founder and CEO, Josep Bassaganya-Riera, will participate in the UBS Virtual Biotechnology Private Company Symposium on September 18-19, 2024. The symposium offers a platform for NImmune to engage with leading investors and discuss its innovative approach to immunoregulatory drug development.
Omilancor: A Phase 3 Asset
A key highlight of NImmune's presentation will be omilancor, a wholly-owned, oral, once-daily therapeutic currently in Phase 3 development. Omilancor is designed to be gut-restricted and represents a first-in-class approach to treating ulcerative colitis (search) and Crohn’s disease (search) by targeting LANCL2 (search).
Precision Immunology Approach
NImmune leverages a discovery platform that integrates advanced computational modeling, artificial intelligence (AI), and bioinformatics with biomedical research. This platform enables the efficient clinical development of drug candidates with a high probability of success, aiming for New Drug Application (NDA) filings and commercialization.
Clinical Data and Potential
Omilancor's Phase 2 proof-of-concept data indicates a potentially best-in-class efficacy and safety profile. The ongoing Phase 3 development aims to confirm these findings and address the unmet needs in ulcerative colitis (search) and Crohn’s disease (search) treatment.